# Entecavir

## Baraclude 0.5mg

##### 

| TAH Drug Code      | OBAR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of chronic HBV infection in adults with evidence of active viral replication & either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive, compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Patients who previously demonstrated hypersensitivity to entecavir or any of the components of Baraclude.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Diarrhea, dyspepsia, nausea, vomiting. Fatigue. Headache, dizziness, somnolence. Insomnia. Gastrointestinal: Nausea (all grades, 3% or greater; grade 2 to 4, less than 1% ) Neurologic: Dizziness (all grades, 3% or greater; grade 2 to 4, less than 1% ), Headache (all grades, 3% or greater; grade 2 to 4, 2% to 4% ) Other: Fatigue (all grades, 3% or greater; grade 2 to 4, 1% to 3% )                                                                                                                                                                                                                                                              |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## 1mg BARACLUDE

##### 

| TAH Drug Code      | OBAR1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 2 years and older with evidence of active viral replication and either evidence of persistent transaminase elevations or histologically-active disease. Note: In adults, indication is based on data in patients with compensated and decompensated liver disease; in children, indication is based on data in patients with compensated liver disease.                                                                                                                                                                                                             |
| Dosing             | Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive, compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity to entecavir or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Diarrhea, dyspepsia, nausea, vomiting. Fatigue. Headache, dizziness, somnolence. Insomnia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

